MedPath

Medico-economic Study of the Lobo-isthmectomy Assisted Robot

Not Applicable
Terminated
Conditions
Lobo-isthmectomy
Interventions
Other: lobo-isthmectomy assisted robot
Registration Number
NCT02961322
Lead Sponsor
University Hospital, Montpellier
Brief Summary

This is a study of health economics longitudinal cohort on the evaluation of direct medical cost of a surgical technique based on the use of an innovative device (the da Vinci® surgical robot Si) and its comprehensive care.

Detailed Description

Over 50,000 thyroidectomies are performed each year in France. The externally surgery produces satisfactory results, but it nevertheless remains a risk of complications in the order of 10 to 20%. Moreover, the patients operated by traditional externally have a basi-cervical visible scar which is a major concern for many of them. The team of Montpellier University Hospital is a pioneer in the use of the technique of endoscopic thyroidectomy under robotic assistance that saves totally cervical scarring for patients, but also decrease the rate of complications. This technique based on the use of the da Vinci robotic system if justified, depending on the manufacturer and the scientific literature, with its minimally invasive character, an amplitude of greater movement than the hand of man, and movements called intuitive that reduce tremors instruments during the operation (Patel 2008). In France and in Europe, there is a growing demand from patients and surgeons to access the surgical technique. An assessment of the real and specific cost of this technique and its overall management is essential in order to assess the financial impact of the introduction of this surgery for our hospitals, or no data is available on this in Literature.

The main objective of this study is to describe the direct medical cost of the treatment of thyroid Lobo-Isthmectomy Robot-Assisted (LIRA) with a follow-up 12 months. The secondary objectives of this research are to determine the rate of laryngeal paralysis, the rate of complications specific to access axillary robot, the size of the incision made for surgery, the number of channel conversion transaxillary assisted robot traditional externally, to assess the satisfaction of each patient over his scar, pain over time, the evolution of potential disorders sensitivity of anterior chest wall, the vocal functional suites and quality of life self-administered questionnaire (Voice handicap Index VHI 10 and Short Forme SF-36), and finally to compare the cost of care by the robot with the average cost of a conventional surgery.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
9
Inclusion Criteria
  • Patient candidate for thyroid lobectomy or lobo-isthmectomy for benign nodular disease
  • normal laryngeal mobility (clinical evaluation by an ENT (Ear-Nose-Throat) Doctor)
  • breast cancer absence being supported
  • No suspected thyroid cancer
  • Nodules size <6cm
  • Confirm Benin character nodules by fine needle biopsy made within 6 months prior to patient inclusion
  • Patient available for post-operative follow-up of 12 months
Exclusion Criteria
  • Patient participating or having participated in another interventional study in the previous 3 months or exclusion period determined by a previous study
  • Patient under guardianship or trusteeship or under judicial protection
  • Inability to give informed patient information
  • Pregnant women, breastfeeding or parturient
  • Contraindications (or incompatible combination therapy) for a necessary treatment in this study
  • contraindication to general anesthesia
  • Emergencies
  • Breast Cancer being supported
  • treatment or surgical sentinel node of the planned breast cancer
  • thyroid nodule ranked in the ultrasound TIRADS 5 (Thyroid image reporting and data system)
  • Fine needle aspiration biopsy with BETHESDA score result 5 and 6
  • Plunging Nodule

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
lobo isthmectomylobo-isthmectomy assisted robot-
Primary Outcome Measures
NameTimeMethod
direct medical cost12 months
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath